Eur Rev Med Pharmacol Sci 2021; 25 (21): 6782-6796
DOI: 10.26355/eurrev_202111_27123

Acute severe SARS COVID-19 patients produce pro-resolving lipids mediators and eicosanoids

P.-A. Regidor, X. De La Rosa, F.G. Santos, J.M. Rizo, R. Gracia Banzo, R.S. Silva

Exeltis Healthcare, Ismaning, Germany. pedro-antonio.regidor@exeltis.com


OBJECTIVE: This study aimed to evaluate the eicosanoid and pro resolutive parameters in SARS COVID-19 patients with the severe acute respiratory syndrome.

PATIENTS AND METHODS: Fourteen male patients with an acute respiratory syndrome caused by SARS COVID-19 and four healthy controls were evaluated by measuring the following parameters in plasma: Polyunsaturated fatty acids: EPA, DHA, ARA, and DPA. Specialized Pro-resolving mediators (SPMs) (including monohydroxy-containing precursors 17-HDHA, 18-HEPE, 14-HDHA) resolvins, maresins, protectins, and lipoxins. The eicosanoids group included prostaglandins, thromboxanes, and leukotrienes.

RESULTS: Plasma from COVID-19 patients presented higher amounts of pro-inflammatory and pro-thrombotic lipid mediators as compared to healthy subjects (65.7 pg/ml vs. 10.2 pg/ml), including thromboxane (2142.6 pg/ml vs. 10.4 pg/ml), and the ratio between total plasma pro-inflammatory mediators versus total SPM’s was 13.2 to 0,4, respectively.

CONCLUSIONS: A clear disbalance favoring the pro-inflammatory axis is described, showing the need to perform future clinical interventions in these patients using SPM’s or monohydroxylated lipid mediators derivates from fatty acids.

Free PDF Download

To cite this article

P.-A. Regidor, X. De La Rosa, F.G. Santos, J.M. Rizo, R. Gracia Banzo, R.S. Silva
Acute severe SARS COVID-19 patients produce pro-resolving lipids mediators and eicosanoids

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 21
Pages: 6782-6796
DOI: 10.26355/eurrev_202111_27123